Overview

A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Status:
Withdrawn

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy, safety, tolerability, and pharmacokinetics (PK) of meropenem-vaborbactam compared to piperacillin/tazobactam for 7 to 14 days in the treatment of hospitalized adults who meet clinical, radiographic, and microbiological criteria for hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).

Phase:

Phase 3

Details

Lead Sponsor:

Melinta Therapeutics, Inc.

Treatments:

Meropenem
Penicillanic Acid
Piperacillin
Piperacillin, Tazobactam Drug Combination
Tazobactam
Thienamycins
Vaborbactam